Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penny-Wise Payment for Generics

This article was originally published in RPM Report

Executive Summary

Congress is cutting what the Medicaid program will pay pharmacies for generic prescriptions. Big chains warn that could mean they use brands more.

You may also be interested in...



Here's a Switch: Pharmacies Prepare to Push Brands First in Medicaid

Pfizer's Lipitor is taking a beating as payors push use of generic statins wherever possible. But Lipitor and many other blockbuster brands may get some unexpected relief when Medicaid changes its payment rules for generics next year.

Here's a Switch: Pharmacies Prepare to Push Brands First in Medicaid

Pfizer's Lipitor is taking a beating as payors push use of generic statins wherever possible. But Lipitor and many other blockbuster brands may get some unexpected relief when Medicaid changes its payment rules for generics next year.

Reinventing Pharmacy: The Price Increase for Caremark Could Be a Price Decrease for Manufacturers

The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel